HIK Hikma Pharmaceuticals Plc

TIDMHIK

RNS Number : 6864E

Hikma Pharmaceuticals Plc

08 July 2019

London, 8 July 2019 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) will announce its interim financial results for the six months ended 30 June 2019 on Friday 09 August 2019.

A presentation and webcast for analysts will be held at 9.30am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.

To join via conference call please dial:

United Kingdom 0800 640 6441

United Kingdom (local) 020 3936 2999

USA 1 646 664 1960

All other locations +44 20 3936 2999

Access code: 706288

Webcast Link:

https://webcast.openbriefing.com/hikma-9819/

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://webcast.openbriefing.com/hikmaPR2018/.

A recording will be available until 10th February 2020. Please see playback details below:

UK 020 3936 3001

USA 1 845 709 8569

All other locations: +44 20 3936 3001

Access code: 732473

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

 
 Susan Ringdal 
  EVP, Strategic Planning and Global        +44 (0)20 7399 2760/ +44 7776 
  Affairs                                    477050 
 
   Lucinda Baker                            +44 (0)20 7399 2765/ +44 7818 
   Deputy Director of Investor Relations     060211 
 
   Virginia Spring                          +44 (0)20 3892 4389/ +44 7973 
   Senior Investor Relations Manager         679502 
 

FTI Consulting

 
 Ben Atwell/Andrew Ward    +44 (0)20 3727 1000 
 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

(c)2019 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORFMGGNFKNGLZM

(END) Dow Jones Newswires

July 08, 2019 04:00 ET (08:00 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024